|
MechanismIL-23R inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Mopac Biologics, Inc.
0 Patents (Medical) associated with Mopac Biologics, Inc.
100 Deals associated with Mopac Biologics, Inc.
100 Translational Medicine associated with Mopac Biologics, Inc.